Comorbidity in bipolar disorder: a framework for rational treatment selection
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Bipolar disorders are heterogeneous disorders often requiring multimodality treatment. The expanding pharmacopeia for bipolar disorders invites the need for a treatment framework that both recognizes and anticipates the multidimensionality and comorbidity of the illness. No available neurotherapeutic agent is singularly efficacious for the complete mélange of bipolar symptomatology. An apparent paradox has emerged in the management of bipolar disorder; whilst results from rigorous controlled monotherapy trials suggest that a disparate assortment of neurotherapeutic agents are efficacious in distinct phases of bipolar disorder, the majority of tertiary‐treated bipolar patients receive polypharmacotherapeutic regimens. The evidentiary base for polypharmacotherapy is sparse and has recently become an area of active research focus. In the interim, clinicians are encouraged to invoke an organizational schema for the treatment of bipolar disorder that considers the spectrum of effectiveness of putative and established mood stabilizers. This schema should be further informed by the treatment data for comorbid and accessory conditions. The authors propose a schema to provide the impetus for further work in the area. Copyright © 2004 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites
Robins, L. N. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790210031005 · Cited by 2,550 · cited 1×
“The Epidemiologic Catchment Area (ECA) database reported a lifetime rate of obsessive compulsive disorder (OCD) among patients with bipolar disorder of 21% (Chen and Dilsaver, 1995a), which is substantially higher than the 2.5% reported in the general population (Robins et al., 1984).”
InfluentialExcess mortality of mental disorder
Harris, C., & Barraclough, B. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.1.11 · Cited by 1,881 · cited 1×
“In population-based studies, mortality from cardiovascular disease is almost two-fold higher among patients with bipolar disorder compared with the general population (Weeke et al., 1987; Sharma and Markar, 1994; Harris and Barraclough, 1998; Osby et al., 2001).”
Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1873 · Cited by 1,525
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 1×
“The symptomatic structure of bipolar disorder is largely depressive in nature, hinting that anxiety and bipolar disorder may also be common (Judd et al., 2003).”
Excess Mortality in Bipolar and Unipolar Disorder in Sweden
Ösby, U., Brandt, L., Correia, N., Ekbom, A., & Sparén, P. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.844 · Cited by 1,120 · cited 2×
“Mortality from natural causes including endocrine, cardiovascular, respiratory, gastrointestinal and urogenital causes was 1.9–3.7 times higher in males and 1.2–4.8 times higher in females compared with the general population (Osby et al., 2001).”
InfluentialHirschfeld, R. M. A., Lewis, L., & Vornik, L. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0209 · Cited by 922
The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members
Lish, J. D., Dime-Meenan, S., Whybrow, P. C., Price, R. A., & Hirschfeld, R. M. A. (1994) · Journal of Affective Disorders · doi:10.1016/0165-0327(94)90104-x · Cited by 897
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 10×
“Cyclothymic OCD: a distinct form?”
InfluentialMcElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484 · cited 2×
“Topiramate has demonstrated efficacy in the short-term treatment of binge eating disorder associated with obesity in open-label (Shapira et al., 2000; Appolinario et al., 2002) and double-blind trials (McElroy et al., 2003).”
Davidson, J. R. T., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R., & Farfel, G. M. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.485 · Cited by 470
Psychological and Pharmacological Treatments of Social Phobia: A Meta-Analysis
Fedoroff, I. C., & Taylor, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00011 · Cited by 396 · cited 1×
“Meta-analyses of trials in social anxiety disorder, have demonstrated response rates with selective serotonin reuptake inhibitors (SSRIs) from 40% to 68% (van der Linden et al., 2000; Fedoroff and Taylor, 2001).”
Substance abuse in bipolar disorder
Cassidy, F., Ahearn, E. P., & Carroll, B. J. (2001) · Bipolar Disorders · doi:10.1034/j.1399-5618.2001.30403.x · Cited by 385 · cited 3×
“The presence of comorbid substance abuse was associated with a poorer outcome, with lower rates of remission (Goldberg et al., 1999) and more psychiatric hospitalizations (Sonne et al., 1994; Cassidy et al., 2001).”
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344 · cited 1×
“Similarly, in a randomized placebo-controlled trial, Bray et al. demonstrated a significantly greater weight loss with all doses of topiramate (64, 96, 192, 384 mg/day) in 385 obese study subjects (Bray et al., 2003).”
Donovan, S. J., Stewart, J. W., Nunes, E. V., Quitkin, F. M., Parides, M., Daniel, W., Susser, E., & Klein, D. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.818 · Cited by 273 · cited 2×
“Divalproex was superior to placebo for explosive temper and mood liability (Donovan et al., 2000).”
A History of Substance Abuse Complicates Remission From Acute Mania in Bipolar Disorder
Goldberg, J. F., Garno, J. L., Leon, A. C., Kocsis, J. H., & Portera, L. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1103 · Cited by 238
Anxiety as a Correlate of Response to the Acute Treatment of Bipolar I Disorder
Feske, U. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.956 · Cited by 230 · cited 2×
“A history of comorbid panic attacks or anxiety symptoms was associated with non-remission, longer time to remission, a greater number of medications to achieve remission, and more severe medication side effects (Feske et al., 2000).”
Frankenburg, F. R., & Zanarini, M. C. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0511 · Cited by 221
Substance Abuse and Bipolar Affective Disorder
SONNE, S. C., BRADY, K. T., & MORTON, W. A. (1994) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199406000-00007 · Cited by 211
van der Linden, G. J., Stein, D. J., & van Balkom, A. J. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200008002-00004 · Cited by 130
Quetiapine in bipolar disorder and cocaine dependence
Brown, E. S., Nejtek, V. A., Perantie, D. C., & Bobadilla, L. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.02229.x · Cited by 122
Comorbidity of obsessive‐compulsive disorder in recovered inpatients with bipolar disorder
Krüger, S., Bräunig, P., & Cooke, R. G. (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.020111.x · Cited by 88 · cited 2×
“(Chen and Dilsaver, 1995b; Ucok et al., 1998; Vieta et al., 1999; Kruger et al., 2000; Frank et al., 2002; Simon et al., 2003), higher frequency of cycle acceleration with increased duration and severity of subsequent episodes (Strakowski et al., 1993; Chen and Dilsaver, 1995b; Goldberg et al.,…”
Perugi, G., Toni, C., Frare, F., Ruffolo, G., Moretti, L., Torti, C., & Akiskal, H. S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00008 · Cited by 61 · cited 6×
“…duration and severity of subsequent episodes (Strakowski et al., 1993; Chen and Dilsaver, 1995b; Goldberg et al., 1999; McElroy et al., 2001; Perugi et al., 2002b), more frequent depressive episodes (Frank et al., 2002; Perugi et al., 2002b) and poorer overall functional outcome (Bowen et…”
InfluentialAdjunctive gabapentin treatment of bipolar disorder
Vieta, E., Martinez-Arán, A., Nieto, E., Colom, F., Reinares, M., Benabarre, A., & Gastó, C. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00514-9 · Cited by 46 · cited 3×
“Data on the efficacy of gabapentin in bipolar disorders are mixed, demonstrating efficacy in open-label (Vieta et al., 2000b; Wang et al., 2002), but not double-blind trials (Pande et al., 2000a).”
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationMcIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31544-0 · Cited by 1,047
Self-citationYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Self-citationYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S. V., MacQueen, G., McIntyre, R. S., Sharma, V., Beaulieu, S., & for CANMAT guidelines group (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00432.x · Cited by 264
Self-citationIntegrated Neurobiology of Bipolar Disorder
Maletic, V., & Raison, C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00098 · Cited by 226
“Microglia act as ambassadors of the immune system (1), monitoring for derivatives of peripheral inflammatory signals.”
BackgroundInfluential
Metadata
- Authors
- McIntyre, R. S., Konarski, J. Z., & Yatham, L. N.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2004-07-30
- Volume
- 19
- Issue
- 6
- Pages
- 369-386
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2161905994
- Cited by
- 71
- References
- 25
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.